Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

@article{SteMarie2009ComparisonOT,
  title={Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.},
  author={Louis-Georges Ste-Marie and Jacques P Brown and JohnF. Beary and Ellen Matzkin and Lynn M Darbie and David Ernest Burgio and Artur J Racewicz},
  journal={Clinical therapeutics},
  year={2009},
  volume={31 2},
  pages={
          272-85
        }
}
BACKGROUND Risedronate 5 mg/d is approved by the US Food and Drug Administration for the treatment and prevention of postmenopausal osteoporosis. Once-monthly dosing options might increase treatment compliance and persistence. OBJECTIVE The aim of this study was to compare the tolerability and efficacy of 3 once-monthly risedronate dosing regimens with those of risedronate 5 mg/d. METHODS This Phase II, 6-month, randomized, double-blind, active-controlled, dose-ranging study was conducted… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Similar Papers

Loading similar papers…